Pulmonary Biosynthesis and Metabolism of Prostaglandins and Related Substances

by Thomas E. Eling* and Ariff I. Ally*

On passage through the lung vascular bed, prostaglandins are removed from the circulation by a transport carrier and subsequently inactivated by intracellular enzymes. However, PGI₂ is not inactivated by the lung in vitro. Although PGI₂ is an excellent substrate for the intracellular enzymes in vitro, PGI₂ is not a substrate for the carrier system. Thus, the transport carrier determines which circulating prostaglandin is inactivated by the pulmonary vascular bed. Also, the lung has a high capacity for forming prostaglandins from arachidonic acid. Considerable differences exist between species in relation to amount and specific prostaglandin formed as determined by incubation of 13C-PGH₂ with pulmonary microsomes. The pulmonary biosynthesis and metabolism of these prostaglandins and related substances are discussed.

It has long been recognized that the lungs have a high capacity for inactivating circulating bioactive substances. The early work of Vane and his colleagues (1) indicated that the circulating prostaglandins (PGs) are extensively inactivated on single passage through the pulmonary circulation. It was subsequently shown (2) that the lung is particularly rich in two enzymes, 15-hydroxy prostaglandin dehydrogenase (PGDH) and 13,14-reductase, that degrade PGs. Thus, it is likely that the lung or its pulmonary vascular bed is a major site for the inactivation of PG present in the circulation.

Other studies have shown that the lung is also rich in enzymes that convert arachidonic acid into PGs and related substrates. In response to a variety of stimuli, both physiological as well as pathological, PGs and related substrates are released into the circulation. Recently, it has been proposed by Gryglewski et al. (3) that the vascular bed of the lung continuously secretes PGI₂ into the circulation and that the lung acts as a natural defense against development of intra-arterial thrombus. Thus, the lung appears to be a unique organ that controls or maintains the levels of a particular circulating prostaglandin.

Metabolism by Lung Subcellular Fractions in Vitro

Studies on the metabolism of prostaglandins in lung tissue indicate that PGs undergo metabolic transformation. First, the hydroxyl group at C-15 is oxidized to a keto group by prostaglandin dehydrogenase (PGDH) followed by reduction of double bond at C-13 by Δ¹³ reductase (Fig. 1). This is accompanied by biological inactivation (4). The enzymes have been purified and extensively studied. PGE₁ is the best substrate having lowest K_m and highest V_max but PGE₂, PGF₁α, PGA₁, and PGA₂ were also substrates with higher K_m values and lower V_max (5). With the discovery of PGI₂ and its nonenzymatic breakdown product 6-keto-PGF₁α by Vane and his colleagues (6) and the potential biological importance of PGI₂, the question of the metabolism of this prostaglandin by PGDH arose. We have investigated the metabolism of PGI₂, 6-keto-PGF₁α and PGF₂α by rat lung 600 g supernatant fortified with NAD⁺.

Incubation of rat lung homogenates with ³H-PGF₂α resulted in the formation of two distinct metabolite

\[
\begin{align*}
\text{PGF}_2\alpha & \rightarrow \text{6-keto PGF}_2\alpha \\
& \rightarrow \text{15-keto PGF}_2\alpha \\
& \rightarrow \text{15-keto-13,14 dihydro PGF}_2\alpha
\end{align*}
\]

Figure 1. Metabolism of prostaglandin by lung prostaglandin dehydrogenase and reductase.
peaks which cochromatographed with authentic 15-keto-PGF$_{2\alpha}$ and 13,14-dihydro-15-keto-PGF$_{2\alpha}$. As found previously, the rat lung seems to lack the 15-keto-prostaglandin reductase that is necessary for formation of the 13,14-dihydro-PG metabolites (7).

Two chromatographic peaks resulted from the incubation of $^3$H-PGI$_2$ or $^3$H-6-keto-PGF$_{1\alpha}$ with rat lung homogenates. The peak remaining closest to the origin cochromatographed with both 6-keto-PGF$_{1\alpha}$, the breakdown product of PGI$_2$, and 6-keto-13,14-dihydro-PGF$_{1\alpha}$. The peak closest to the solvent front could be either 6,15-diketo-PGF$_{1\alpha}$ or 6,15-diketo-13,14-dihydro-PGF$_{1\alpha}$ or a mixture of these metabolites. Further attempts to separate these metabolites by means of other TLC systems were unsuccessful. However, Wong et al. (8) have recently used GC-MS to isolate and identify 6,15-diketo-PGF$_{1\alpha}$ as a major metabolite formed from incubation of PGI$_2$ with the cytoplasm of various blood vessels. The major metabolite formed in our incubation system was, therefore, most likely to be 6,15-diketo-PGF$_{1\alpha}$. Since PGI$_2$ is relatively stable at pH used in the incubation, we conclude that the 6,15-diketo-PGF$_{1\alpha}$ found in this incubation system probably arose from nonenzymatic hydrolysis of 15-keto-PGI$_2$ during the workup procedure.

PGI$_2$ and PGF$_{2\alpha}$ appeared to be metabolized to comparable extents by rat lung homogenates over a 10-min incubation period (Fig. 2). After 4 min 16% of both the PGF$_{2\alpha}$ and PGI$_2$ was degraded, while after 10 min, 41% of the PFG$_{2\alpha}$ was metabolized compared to 35% of the PGI$_2$ (7). In contrast, 6-keto-PGF$_{1\alpha}$ was only minimally metabolized (6% at 10 min). Little or no metabolism ($\leq 2\%$) of any PG was obtained with boiled homogenates.

McGuire and Sun (9) have investigated the metabolism of PGI$_2$ by a partially purified prostaglandin dehydrogenase obtained from rhesus monkey. These workers also found that PGI$_2$ but not 6-keto-PGF$_{1\alpha}$ was an excellent substrate for PGDH. PGI$_2$ was oxidized at 4 to 6 times faster than 6-keto-PGF$_{1\alpha}$. The $k_m$ for PGI$_2$ was found to be 7.4 $\mu$M compared to 14.5 $\mu$M for PGI$_1$ and 56 $\mu$M for PGF$_{2\alpha}$. These data indicate that PGI$_2$ but not 6-keto-PGF$_{1\alpha}$ is the physiological substrate for pulmonary PGDH. The sequence of PGI$_2$ metabolism is the formation of 15-keto-PGI$_2$ followed by nonenzymatic breakdown to 6,15-diketo-PGI$_{1\alpha}$ (Fig. 3).

Studies on the Transport of PG by Pulmonary Tissue

The early work of Vane and his associates showed that prostaglandin E$_{11}$, E$_2$ and F$_{2\alpha}$ were rapidly and extensively inactivated in a single passage through the lung vasculature (1). Reports from various investigators reveal no species variation in the inactivation of PGE and PGF$_{2\alpha}$ from the circulation by the lung. Cat, dog, rabbit (1) and rat (10) lungs have all been shown to inactivate PGE and PGF$_{2\alpha}$ from the pulmonary circulation. However, guinea pig (11) and rabbit (12) isolated perfused lungs (IPL) have been shown to metabolize A-type PGs, while cat (13), dog (14), and rat IPL (10) have not. PGA$_1$ appears to be a substrate for the intracellular prostaglandin dehydrogenase (PGDH) (15). Thus, the species differences in metabolism may be the result of a species difference in accessability to the intracellular degradative enzymes. These facts, together with the rapidity of the processes, suggested to us that a carrier or a transport system was responsible for the rapid removal of PGs from the circulation and that the transport system imparts selectivity to the pulmonary inactivation system.

In order to study the removal mechanism, measurement of the initial velocity or unidirectional flux of PGs from the perfusate into the intact lung cells was necessary. We therefore used an isolated perfused rat lung preparation which permitted measurement of the initial velocity at a constant concentration of PG in the arterial perfusate. Previously published work details the specifics of the measurements (10).

The initial velocity of PGE$_1$ uptake into the lung was saturated with increasing concentrations of PGE$_1$ in the

![Figure 2](image-url)  
**Figure 2.** Metabolism of $^3$H-PGI$_2$, $^3$H-PGF$_{2\alpha}$ and $^3$H-6-keto-PGF$_{1\alpha}$ by rat lung homogenate.

![Figure 3](image-url)  
**Figure 3.** Pathway for the metabolism of PGI$_2$ and 6-keto PGF$_{1\alpha}$ by prostaglandin dehydrogenase.
perfusion (Fig. 4). This type of relationship between the initial velocity and the perfusate concentration suggests that a carrier-mediated or transport process was involved in the removal of PGE₁ by the lung. Diffusion or binding of the PG to lung tissue would give a linear relationship between the initial velocity and perfusate concentration.

We have also examined the rates of removal of PGF₂α, PGB₁, PGA₁ and 15-keto-PGF₂α from the vasculature to the lung. Both removal and metabolism was observed with PGF₂α. This suggests that definitive substrate specificity exist for the carrier molecule. PGA₁ is metabolized in vitro by lung PGDH. However, the PGA₁ metabolism is not observed in vivo. This may be explained by the fact that PGA₁ is not a substrate for the carrier molecule. Further support for the existence of a carrier or transport system in rat lung was obtained by inhibitor studies. The addition of a second PG substrate for example, PGF₂α, significantly inhibited the removal of the first substrate PGE₁. The addition of a nonsubstrate, i.e., PGA₁ did not inhibit the removal of the substrate PGE₁ for the transport system. Further studies showed that PGF₂α competitively inhibited the uptake of PGE₁. Thus, saturation of the initial velocity with respect to perfusate concentration, the inhibition of the removal of one PG by another, and the concentration dependence of this inhibition, support our hypothesis of a transport system.

The substrate specificity for the inactivation of circulating PGs appears to reside with the transport carrier since both PGE₁ and PGF₂α are removed, but PGA₁ and 15-keto-PGF₂α are not removed from the circulation. We have studied the structural requirement of the PG molecules essential for transport from the circulation into the lung. As seen in Table 1 (16), PGE₁, PGE₂, PGF₁α, PGF₂α, PGF₂β and to some extent PGD₂ and PGD₁ were removed from the circulation into the lung. PGA₁, PGB₁ and various metabolites of the classical PGs were not removed. In addition, the methyl esters of PGs were not substrates for the transport system. With the discovery of PGI₂ and its potential importance in controlling intra-arterial thrombosis, it was important to determine if PGI₂ was a substrate for the transport system. Studies with in vitro incubation systems (see above) indicate that PGI₂ was an excellent substrate for pulmonary PGDH. However, using bio-assay techniques, Dusting et al. have studied the disappearance of PGI₂ in the circulation of the dog (17). Their work indicated little or no inactivation of PGI₂ on passage through the lung, while extensive inactivation occurred in the liver and hind quarters. Similarly, the conclusion that PGI₂ escapes pulmonary metabolism has been reached by Bolger and co-workers while studying the renal actions of PGI₂ (18), and by Armstrong et al. in a study of hypotension induced by PGI₂ (19). The data suggest that PGI₂ is not a substrate for the carrier system. Since PGI₂ was not stable at pH 7.4, determining the removal of PGI₂ from the circulation into the lung required a different experimental approach than measurement of the initial velocity. Uptake was studied by indicator dilution techniques. The effluent from an isolated rat lung was collected in approximately 1-sec intervals after injection of a ³H-PG and the vascular marker ¹⁴C-dextran. For PGF₂α (a transport substrate), analysis of the effluent radioactivity showed a displaced tritium peak indicating that the PGF₂α was taken into the vascular cells (Fig. 5a). Analysis of the effluent indicated that the ³H-PGI₂ was extensively degraded. However, after bolus injection of ³H-PGI₂ or ³H-6-keto-PGF₁α mixed with ¹⁴C-dextran, analysis of the effluent indicated the mean transit times for both PGI₂ and 6-keto-PGI₁α (Fig. 5a) were identical to the vascular marker dextran. Furthermore, neither PGI₁ nor 6-keto-PGF₁α was metabolized during passage through the lung. Thus, PGI₂ and 6-keto-PGF₁α are not

![Figure 4. Saturation of PGE₁ uptake velocity with perfusate concentration.](image)

| Substance       | Uptake velocity (relative to PGE₁) |
|-----------------|------------------------------------|
| PGE₁            | 1.0                                 |
| PGE₂            | 0.86                                |
| PGF₁α           | 0.68                                |
| PGF₂α           | 1.20                                |
| PGF₂β           | 1.0                                 |
| PGA₁            | 0                                   |
| PGB₁            | 0                                   |
| PGB₂            | 0.57                                |
| PGD₁            | 0.25                                |
| 15(S)methyl-PGF₂α | 1.45                            |
| 15(R)methyl-PGF₂α | 0                                |
| 15-keto-13,14-dihydro-PGE₁ | 0        |
| 13,14-dihydro-PGE₁ | < 0.2                          |
| 13,14-dihydro-PGF₂α | < 0.4                        |
| PG methyl esters | 0                                  |
| 15-epi-PGE₂     | 0                                   |
| 15-epi-PGF₂α    | 0                                   |
substrates for the transport system; thus, the biological half-life of PGI₂ is not controlled by passage through the pulmonary vascular bed.

The present studies (7,10,16) show there are apparently three critical portions (Fig. 6) of the PG molecule necessary for transport into lung tissue: the acid group at C-1, the oxygen function, particularly a hydroxyl group at C-11, and a hydroxyl group at C-15 in the S configuration. The steric relationship between these groups is important since reduction of the 13,14-double bond reduces or abolishes transport, and changing the C-15 hydroxyl group from S to R configuration abolishes transport.

Evidence for the importance of the acid group was derived from the observation that the methyl esters of PGE₁, PGE₂, and PGF₂α were not taken up into the perfused lung. In contrast, the methyl esters of PGs are substrates for lung prostaglandin dehydrogenase (PGDH) (15). The importance of an oxygen function at C-11 was illustrated by the lack of uptake observed for PGA₁ and PGB₁. The presence of a carbonyl group (PGD₂ and PGD₁) rather than a hydroxyl group reduces uptake by the rat isolated perfused lung. The presence of a hydroxyl group at C-15 appears to be an absolute requirement for removal of PGs from the circulation by the lung. Conversion of the hydroxyl group to a keto group abolishes uptake. Moreover, the configuration of the C-15 hydroxyl group is critical. 15(R) methyl-PGF₂α was not removed from the circulation by the lung, whereas approximately 90% of the 15(S) methyl-PGF₂α was removed. In addition, the 15-epi isomers of PGE₂ and PGF₂α did not inhibit the removal of PGE₁. Alteration of the functional groups at C-9 does not affect the removal. PGF₂β, which has a hydroxyl group at C-9 and PGE₂, with a keto group at C-9 are substrates for the transport system. Therefore, changing the hydroxyl group at C-9 from an α to a β configuration had little effect. However, since PGI₂ contains a ring structure between the 6 and 9 carbon atoms, the position of the side chain containing the carboxylic acid moiety is significantly altered in relation to the rest of the molecule. In 6-keto-PGF₁α, a hemiketal ring between the keto group at C-6 and the hydroxyl at C-9 can be formed. The conditions that govern the equilibrium between the open and closed forms are not known. In the closed form of 6-keto-PGF₁α, the hemiketal ring significantly alters the position of the carboxylic side chain. In the open form, the planar configuration of the carboxyl group may change the position of the side chain, modifying the PG hairpin structure. Another possible explanation for the lack of uptake of 6-keto-PGF₁α is that the presence of an additional oxygen molecule may change the electronic characteristics of this PG, subsequently altering the binding to the transport carrier. Thus, the geometric configuration of the C-1 carboxyl group in relation to the C-15 hydroxyl group and the C-11 oxygen function is different in PGI₂ and 6-keto-PGF₁α compared to that of other PGs. Our present results indicate that the three functional groups on the PG molecule that are necessary for transport
into lung tissue may need to form a precise geometric configuration in order for transport to occur.

An alternative explanation for the lack of pulmonary transport of PG12 and 6-keto-PGF1α may involve the oxygen function at C-9. In PG12 and the hemiketal form of 6-keto-PGF1α, the oxygen function becomes part of a ring system. This points to the possibility that the presence of a free hydroxyl or carbonyl group at C-9 is an additional requirement for pulmonary transport of PGs. It could, therefore, be the difference in geometric configuration and/or the lack of a free oxygen function at C-9 that prevent PG12 and 6-keto-PGF1α from being transported into lung tissue.

Thus, the pulmonary inactivation system consists of transpor carrier and intracellular enzymes as shown in Figure 7. The selectivity of the transport system in the lung and hence the selectivity of the pulmonary inactivation of PGs may have important physiological significance. The pulmonary removal and inactivation of some PGs may serve to protect the arterial circulation from potentially deleterious effects of these PGs. Since PG12 presumably exerts beneficial effects including inhibition of platelet aggregation (19) and has been implicated in the prevention of arterial thrombosis (6), it would be disadvantageous for it to be removed during passage through the pulmonary bed. Recent studies (3) have, in fact, shown that the lung in vivo actually generates PG12, and it has been proposed that PG12 may be a circulating hormone (20), although some evidence exists to the contrary. Thus, the lung may play an important role in the prevention of arterial thrombosis.

Inhibition of Pulmonary Inactivation

The addition of various chemicals or drugs to the perfusate altered the rate of removal and/or rate of PG metabolism by the lung. Several PG antagonists, polyphloretin phosphate (PPP) and diphloretin phosphate (DPP) were effective primarily by inhibiting the transport system (4). The organic acid transport inhibitor, bromocresol green, was a potent inhibitor of the transport system (16). The exposure of lung to various environmental pollutants significantly affected the pulmonary inactivation of circulating PGs. Bakhle et al. (21) recently investigated the effect of cigarette smoke on the metabolism of vasoactive hormones by the rat isolated lungs and reported that exposure to smoke decreased the inactivation of circulating PGE2.

We have examined the effect of exposure of guinea pig and rats to the environmental gases, NO2, SO2 and O2 (22). As measured by in vitro assay techniques, prostaglandin synthetase was not altered by the exposure. However, exposure to O2 and NO2 but not SO2 significantly depressed PGDH activity. Exposure of animals to 100% O2 depressed PGDH (in vitro) with the degree of inhibition dependent on the length of exposure. After 72 hr of O2 exposure, PGDH was depressed by approximately 80%. Exposure of guinea pig to 100% O2 did not apparently alter the transport carrier for PGs in the lung. Kinetic analysis suggested that exposure of the oxidant gases resulted in destruction of PGDH (23).

Cyclo-oxygenase Metabolism of Arachidonic Acid by the Lungs

Prostaglandins have received the attention of pulmonary researchers and physicians for a number of reasons: their interaction by the lungs, their contractile effects on bronchial smooth muscle, and their mixed actions on the pulmonary circulation (24). In recent months other arachidonic acid metabolites, the leukotrienes, have begun to attract similar interests (25).

In the future a complete understanding of the interdependence and interactions among the prostaglandins, thromboxanes, and leukotrienes may provide new insights into the phenomena of immediate hypersensitivity reactions and could be of particular importance in the etiology of human asthma. In this section some aspects of lung prostaglandin biosynthesis, species variation and the use of microsomal preparation to study endoperoxide metabolism will be discussed. The metabolic pathway of arachidonic acid in mammalian cells is summarized in Figure 8, and the detailed biochemistry has been reviewed by Samuelsson et al. (26).

The precise biochemical or pathophysiological factors which lead to abnormal biosynthesis of prostaglandins, prostacyclin and thromboxane by lung tissue are not well understood. A wide variety of stimuli which presumably lead to membrane perturbation may initiate prostaglandin biosynthesis. These stimuli can be broadly categorized into anaphylaxis, chemical or environmental agents and physical stimuli (27).

There is an abundance of literature dealing with the production of thromboxane A2, SRS-A and prosta-
glandins in the guinea pig lung. However, the data for other species are sadly deficient. In 1965, Anggadard (28) described the biosynthesis of PGs from endogenous substrate using lung homogenates of human, monkey, sheep and guinea pig by utilizing GC-MS analysis. Of these four species, human, rat and monkey produced significantly lower amounts of PGF₂α than guinea pig. A large number of compounds produced from endogenous arachidonic acid in guinea pig lung have been conclusively identified by Dawson et al. (29). These are TXB₂, PGE₂, PGF₂α, 15-oxo-PGE₂, 15-oxo-PGF₂α, 15-oxo-13,14-dihydro-PGE₂, and 15-oxo-13,14-dihydro-PGF₂α identified in the effluent from isolated perfused normal guinea pig lungs. In addition, 6-keto-PGF₁α (the spontaneous hydrolysis product of prostacyclin PGL₂; Fig. 8) and a novel oxidihydro derivative of TXB₂ were seen only in sensitized lungs during anaphylaxis. Human lungs have been reported to produce 6-keto-PGF₁α, in vivo (30) and PGE₁, PGE₂ and PGF₂α and RCS(TXB₂) in vitro (31). Recently, Palonek et al. (32) provided evidence for the spontaneous and angiotensin-induced release of PGI₂ from cat lungs, using PGI₂ antibodies and a PGI₂ tendon bioassay, while Veolkel et al. (33) described the release of PGI₂ during angiotensin stimulation of rat lung in vitro. Recently, using PGI₂ antibodies, Pace-Asciak et al. (34) obtained data in vivo that argued against the notion that blood PGI₂ exerts an antihypertensive action in spontaneous hypertension (29). Thus, it is still unclear whether PGI₂ is continuously secreted into the circulation in concentrations sufficient to exert biological effects. In sheep, Frolich et al. (35) found that lymph provided a better index of lung tissue prostaglandin biosynthesis. During endotoxin-induced pulmonary hypertension, blood prostaglandin and TXB₂ levels sampled from both the left atrium and the pulmonary artery were unchanged. In contrast, a dramatic 400-fold increase in TXB₂ concentration was seen in lymph using both RIA and GC-MS analysis.

Enhanced lipid peroxidation has been shown to occur in vivo in the lung following exposure to oxidant gases. Exposure to ozone, nitrogen dioxide (36) and oxygen (37) leads to an increase in lipid peroxidation. These oxidant gases have been reported to inhibit pulmonary prostaglandin metabolism (23). Recently, Crutchley et al. (38) reported an increase in the release of TXB₂, 6-keto-PGF₁α, PGE₂ and PGF₂α as a result of inhibition of PGDH by exposure to 100% oxygen. These observations may be related to the phenomenon of increased lipid peroxidation reported by others. Oxygen (5–95%) has been shown to stimulate prostaglandin biosynthesis in tissue slices (39), which suggests a direct effect unrelated to the generation of reactive free radicals or inhibition of 15 hydroxyprostaglandin dehydrogenases.

Rat lung homogenates synthesize predominantly PGI₂ (40), while guinea pig lung homogenates synthesize primarily TXB₂ (41). The dominance of TXB₂ as the major arachidonate metabolite in the guinea pig has been established using lung homogenates (41) and isolated perfused lung (41–44). Earlier, Parkes and Eling (45) identified a novel arachidonate metabolite in guinea pig lung microsomes, which has now been named TXB₂ (46) and is formed by spontaneous hydrolysis of the parent TXA₂ (see Fig. 8).

In a comparative study of 1-¹³C-arachidonic acid metabolism in isolated perfused lung of guinea pig, rat and man, Al Ubaidi and Bakle (47) found that the rat lung provides a better model than guinea pig lung for arachidonic acid metabolism in human lung. A similar conclusion was reached in a study of slow reacting substance of anaphylaxis in rat, mouse, guinea pig and man (48).

There is no doubt that adult lungs biosynthesize TXB₂; it appears that fetal bovine and rabbit lungs produce little TXB₂ (49). In the third trimester, the biosynthesis of PGE₂ by fetal lung of both species increased steadily with little change in either TXB₂ or PGF₂α. Interestingly, a small amount of 6-keto-PGF₁α was seen in rabbit but not bovine fetal lung. In contrast, fetal lamb produced equal amounts of PGE₂, PGF₂α and TXB₂. In an earlier study, Pace-Asciak (50) found that in very young fetal lamb, PGF₂α was the dominant prostaglandin with PGE₂ increasing with gestational age until at term, it equaled PGF₂α. In this latter study, TXB₂ was not assayed. Therefore, it appears that fetal lung prostaglandin biosynthesis is a heterogeneous in terms of product and amounts as it is in adult animals. Thus, clear species and age differences exist in lung prostaglandin biosynthesis.

**Prostaglandin Synthesis by Lung Microsomes**

In experiments using lung microsomes, Tai et al. (51) found that ¹⁴C-arachidonic acid was metabolized by

![Figure 8. Pathways of arachidonic acid metabolism.](image-url)
sheep lung microsomes primarily to TXB$_2$ (14%) and 6-keto-PGF$_{1\alpha}$ (5%); with the inclusion of glutathione, PGE$_2$ became the major metabolite formed. Sun et al. (52) reported that rabbit lung microsomes synthesize both 6-keto-PGF$_{1\alpha}$ and TXB$_2$ from PGH$_2$. As the concentration of PGH$_2$ is increased, the production of 6-keto-PGF$_{1\alpha}$ plateaus while TXB$_2$ increases in a linear fashion. These data suggest that PGI$_2$ synthetase is readily saturated while thromboxane synthetase is not. Thus, if large quantities of endoperoxide are produced in pathophysiological states, TXA$_2$ may become the dominant product in species which normally produce small amounts of TXA$_2$, e.g., rat and man, detected as rabbit aorta contracting substance (46). In their studies with human lung microsomes, Sun et al. (52) were unable to demonstrate endoperoxide metabolism by thromboxane synthetase.

In other studies with porcine lung microsomes, Tai et al. (53) found that $^{14}$C-PGH$_2$ was metabolized to predominantly TXB$_2$. Pyridine (10mM) inhibited TXB$_2$ synthetase, resulting in an increase in the synthesis of both 6-keto-PGF$_{1\alpha}$ and PGE$_2$, without an overall decrease in total product formation. We have found that tranylcypromine (20 µg/mL) inhibits the production 6-keto-PGE$_2$ from the endoperoxide PGH$_2$ by porcine lung microsomes with a significant increase in the synthesis of both TXB$_2$ and PGE$_2$ (Ally and Eling, unpublished data). Thus, the inhibition of enzymes in the prostaglandin cascade produces a significant shift in product formation. It is possible that some form of negative feedback inhibition is responsible since PGE$_2$ has been reported to inhibit PGI$_2$ biosynthesis in rat liver endothelial cells (54).

The heterogeneity of lung arachidonic acid metabolism observed in different species (discussed above) is reflected at the subcellular level. As shown in Figure 9, the metabolic profile for $^{1,14}$C-PGH$_2$ in guinea pig lung microsomes analyzed by HPLC (55) is quite distinct from that in rat lung microsomes; the guinea pig produces little 6-keto-PGF$_{1\alpha}$ but greater than 40% of the total products is TXB$_2$, whereas rat appears to make equivalent amounts of 6-keto-PGF$_{1\alpha}$ and TXB$_2$. In experiments using $^{1,14}$C arachidonic acid and guinea pig lung microsomes, TXB$_2$ represented 28% and 6-keto-PGF$_{1\alpha}$ 6.1% of the cyclooxygenase products. Thus, in our experiments the arachidonic acid metabolic profile is similar, both qualitatively and quantitatively, to that obtained using the endoperoxide PGH$_2$.

As shown in Table 2 human lung microsomes make equivalent amounts of 6-keto-PGF$_{1\alpha}$ and TXB$_2$ while PGE$_2$ is the major product. Of these five animal species, the guinea pig least resembles the human prostaglandin profile, while the rat and mouse appear quite similar. The 6-keto-PGF$_{1\alpha}$/TXB$_2$ ratio in human lungs is close to unity and this ratio is seen in the porcine, bovine, rat and mouse lung. Interestingly, mouse lung makes as much PGE$_2$ from PCH$_2$ as does human lung.

These data, if representative of the extrapulmonary

![Figure 9. HPLC profile of metabolites of PGH$_2$ by (a) rat and (b) guinea pig lung microsomes: (a) rat, (1) 6-keto-PGF$_{1\alpha}$, (2) TXB$_2$, (3) PGF$_{2\alpha}$, (4) PGE$_2$, (5) PGD$_2$, (6) HHT; (b) guinea pig, (1) 6-keto-PGF$_{1\alpha}$, (2) TXB$_2$, (4) PGE$_2$, (5) HHT.](image)

Table 2. PGH$_2$ metabolism by lung microsomes.$^a$

| Species     | 6-Keto-PGF$_{1\alpha}$ | TXB$_2$ | PGF$_{2\alpha}$ | PGE$_2$ | PGD$_2$ |
|-------------|------------------------|---------|-----------------|---------|---------|
| Human$^c$   | 14.7 ± 1.4             | 17.9 ± 4.2 | 12.9 ± 0.9      | 23.1 ± 2.6 | 14.6 ± 1.2 |
| Porcine     | 25.3 ± 2.8             | 21.9 ± 3.7 | 5.1 ± 1.7       | 6.3 ± 0.6 | 4.1 ± 1.1 |
| Bovine      | 26.0 ± 2.0             | 26.0 ± 1.0 | 4.0 ± 1.0       | 3.4 ± 1.7 | ND      |
| Rat         | 23.0 ± 5.0             | 19.0 ± 3.2 | 9.0 ± 0.0       | 16.0 ± 1.0 | 5.0 ± 1.0 |
| Guinea pig  | 3.0 ± 0.6              | 43.0 ± 2.0 | 2.0 ± 1.0       | 3.0 ± 1.0 | ND      |
| Mice        | 10.2 ± 1.2             | 7.1 ± 0.8  | 4.4 ± 0.5       | 23.4 ± 3.4 | 7.4 ± 0.3 |

$^a$ Analysis by HPLC-radiometric procedure.

$^b$ Values are means ± SD, N = 4; ND = not detectable.

$^c$ Macroscopically normal lung samples obtained from patients undergoing resection for cancer.
prostaglandin profile in the lung, suggest that the bronchioles and other nonvascular lung elements are typically exposed to a wide range of prostaglandins, of which two (PGI₂, PGE₂) have been shown to be bronchodilators and three (TXA₂, PGD₂ and PGF₂α) to be bronchoconstrictors. It is suggested that alterations in this balance together with abnormal levels of lipoxigenase products may be responsible for respiratory distress in lung disease (3).

These data discussed here suggest that lung parenchymal microsomes may provide a clear picture of biochemical changes in the prostaglandin and hydroxy fatty acid profiles in pathophysiological conditions of unknown etiology or exposure to airborne environmental pollutants. Of the five animal models examined, the rat appears to be a good choice for further studies since its prostaglandin profile is similar to man and it has the added convenience of being readily available, inexpensive and manageable.

### Lung Thromboxane and Prostaglandin Secretion

Gryglewski and colleagues (3,56) have proposed that the lung continuously secretes PGI₂ into the circulation. The lung is highly vascularized and has large numbers of endothelial cells which are highly active in producing PGI₂. Control of PGI₂ release from the lung is not understood. We have found (57) using the isolated perfused rat lung, that PGI₂ measured by RIA of 6-keto-PGF₁α and TXA₂ measured by RIA of TXB₂, are continuously released into the perfusate. The concentration of TXB₂ was approximately 1/5 that of the PGI₂ detected by RIA of 6-keto-PGF₁α (6 ng/min TXB₂ vs. 33 ng/min). Increasing the rate of respiration increased the release of both TXA₂ and PGI₂, but PGI₂ release appear to be preferentially stimulated. At normal respiration rate (50/min) the ratio of 6-keto-PGF₁α to TXB₂ was 5:1, but at 100/min the rate increased to 11:1 (Fig. 10). Thus, measurement of PGI₂ in perfuse or blood could be highly variable dependent, in part, on the rate of respiration.

There is evidence for considerable species differences in the secretion of PGI₂ and TXA₂ by lung. Alabaster (42) found that guinea pig lung metabolized infused PGH₂ (800 ng) to primarily TXA₂ (101 ± 13 ng) and PGI₂ (10–16 ng), whereas in rabbit lung effluent only unmetabolized PGH₂ (46 ± 9 ng) and some PGE₂ (26 ± 10 ng) were detected. The PGE₂ seen may represent a spontaneous decomposition product from PGH₂. Similarly, Boyd and Eling (68) reported that rat lung significant amounts of PGI₂ but guinea pig produces only very small amounts of PGI₂ from PGH₂ whereas guinea pig lung was found to make primarily, TXA₂. However, guinea pig platelets appear to be very sensitive to PGI₂.

It is now apparent that differences among the species of guinea pig may be identified pharmacologically. Indomethacin infused into guinea pig and rabbit pulmonary vascular beds produced qualitatively dissimilar effects on bioassayable products of arachidonic acid metabolism (42). In guinea pig lung, low concentrations of indomethacin (10 mM) preferentially inhibited primary prostaglandin formation without affecting TXA₂ production. In rabbit lung, this same indomethacin concentration preferentially inhibited TXA₂ biosynthesis. In both guinea pig and rabbit, indomethacin at higher concentrations inhibited the biosynthesis of all prostaglandins. In these studies, Alabaster (42) found that rabbit thromboxane synthetase was very sensitive to inhibition by imidazole (50 μM). In contrast, guinea pig thromboxane synthetase required 50 to 100-fold higher concentrations of imidazole for an equivalent effect. However, inhibition studies must be viewed with caution since inhibitors

![Figure 10. Effect of respiration rate on the release of TXB₂ and 6-keto-PGF₁α by rat perfused lung.](image-url)
may have effects other than inhibition of the enzyme in question and the effect may not be as easily interpreted as presumed. For example, Hong et al. (58) found that the PGI2 synthetase inhibitors, 15-HPAA and tranylcypromine, that 15-hydroperoxy arachidonic acid (15-
HPAA) increased the release of arachidonic acid while inhibiting the biosynthesis of prostacyclin and PGE2, whereas tranylcypromine decreased the release of arachidonic acid and the biosynthesis of prostacycin in isolated endothelial cells.

The origin of thromboxane in the pulmonary vascular effluent is not clear. It is generally advocated that blood vessels do not synthesize thromboxane (26,46). It has been found that the rat mesenteric vascular bed secretes both 6-keto-PGF1α (3–6 ng/min) and TXB2 (0.09–0.15 ng/min) in vitro (59); other researchers have reported similar findings in experiments with arterial preparations of several species (59). Of particular interest is the recent data from Saltzman and co-workers (60), who found that the rabbit intrapulmonary artery (IPA), including the lobular artery and the extrapulmonary artery (lying outside the lung mass), produces both TXB2 and 6-keto-PGF1α in ratios varying from 1:2 to 1:6. In these experiments 14C-arachidonic acid was converted by IPA to 9 ± 1% TXB2 and 16 ± 2% 6-keto-PGF1α. The synthesis of TXB2 and 6-keto-PGF1α from endogenous arachidonic acid was 100 to 200 ng/mg and 500 to 1000 ng/mg tissue, respectively, a ratio of 1:5. In their studies a cascade of biological detectors showed that TXA2 produced by IPA dominated the biological responses, even though GC-MS analysis revealed five times more prostacyclin in the incubation mixture. The data highlight the much greater biological potency of TXA2 and indicate that small changes in PGI2 synthesis, such as in atherosclerosis, may have potentially dramatic biological consequences. Of particular interest is their statement that rabbit lung parenchyma did not produce detectable amounts of TXA2. This is surprising, since Sun et al. (52) reported that rabbit lung microsomes synthesize both PGI2 and TXA2 from PGH2.

It is probable that thromboxane detected in rabbit pulmonary vascular effluent arose primarily in the vascular compartment, since Saltzman et al. (60) were unable to detect TXA2 production by lung parenchyma, although as noted above rabbit lung parenchymal microsomes contain the necessary enzyme complex. Evidence to support the idea that nonvascular lung elements have the capacity to synthesize both TXA2 and PGI2 has been provided by Levine and Alam (61). Using a combined high pressure liquid chromatography–radioimmunoassay procedure these researchers found that endogenous arachidonic acid was metabolized to 65% PGE2, 16% TXB2, 16% PGF2α, and 4% PGI2 in normal human lung cells, whereas rat Type II alveolar cells produced 78% PGE2, 0.2% TXB2, 18.2% PGF2α, and 0.7% PGI2. Such studies culturing different cell types from the lung will in the future provide a better picture of arachidonic acid metabolism in the lung.

REFERENCES

1. Ferreira, S., and Vane, J. Prostaglandins: their disappearance from and release into the circulation. Nature 216: 868–873 (1967).

2. Anggard, E., and Samuelsson, B. Metabolism of prostaglandin E1 in guinea pig lung. The structure of two metabolites. J. Biol. Chem. 239: 4097–4102 (1964).

3. Gryglewski, R., Korbut, R., and Oeetkiewicz, A. Generation of prostacyclin by lung in vivo and its release into the arterial circulation. Nature 273: 765–767 (1978).

4. Crutchley, D., and Piper, P. Prostaglandin inactivation in guinea pig lung and its inhibition. Brit. J. Pharmacol. 57: 197–203 (1974).

5. NaKano, J., Anggard, E., and Samuelsson, B. 15-Hydroxy-
prostanoate dehydrogenase. Prostaglandins as substrates and inhibitors. Eur. J. Biochem. 11: 388–398 (1969).

6. Gryglewski, R., Bunting, S., Flower, R., and Vane, J. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxide. Prostaglandins 12: 685–714 (1976).

7. Hawkins, H., Smith, J., Nicolaou, K., and Eling, T. Studies on the mechanisms involved in the fate of prostacyclin (PGI2) and 6-keto-PGF1α in the pulmonary circulation. Prostaglandins 16: 871–884 (1978).

8. Wong, P., Sun, F., and McGiff, J. Metabolism of prostacyclin in blood vessels. J. Biol. Chem. 253: 5555–5557 (1978).

9. McGuire, J., and Sun, F. Metabolism of prostacyclin: oxidation by Rhesus monkey lung 15-hydroxyl prostaglandin dehydrogenase. Arch. Biochem. Biophys. 185: 92–96 (1978).

10. Anderson, M., and Eling, T. Prostacyclin removal and metabolism by isolated perfused rat lung. Prostaglandins 11: 645–677 (1976).

11. Piper, P., Vane, J., and Wylie, J. Inactivation of prostaglandins by the lung. Nature 225: 600–604 (1970).

12. Hook, R., and Gillis, G. The removal and metabolism of prostaglandin E1 by rabbit lung. Prostaglandins 9: 193–201 (1975).

13. Horton, E., and Jones, R. Prostaglandin A2, A2 and 19-hydroxy-A2; their inactivation on passage through the pulmonary and hepatic portal vascular bed. Brit. J. Pharmac. 37: 705–722 (1969).

14. McGiff, J., Terragno, N., Strand, J., Lee, J., and Longevo, A. Selective passage of prostaglandins across the lung. Nature 229: 742–745 (1970).

15. Hansen, H. 15-Hydroxyprostaga-
din dehydrogenase. A review. Prostaglandins 12: 647–679 (1978).

16. Eling, T., Hawkins, H., and Anderson, W. Structural requirement for and the effect of chemicals on the rat pulmonary inactivation of prostaglandins. Prostaglandins 14: 51–60 (1977).

17. Dusting, G., Mondaca, S., and Vane, J. Disappearance of prostacyclin (PGI2) in the circulation of the dog. Brit. J. Pharmac. 62: 414P–415P (1978).

18. Bolger, P., Eisner, G., Ramwell, P., Slotkoff, L., and Corey, E. Renal actions of prostacyclin. Nature 271: 467–468 (1978).

19. Armstrong, J., Lattimer, N., Moncada, S., and Vane, J. Comparison of the vasodepressor effects of prostacyclin and 6-oxoprostaglandin F1α with those of prostaglandin E2 in rats and rabbits. Brit. J. Pharmacol. 62: 125–130 (1978).

20. Moncada, S., Korbut, R., Bunting, S., and Vane, J. Prostacyclin is a circulating hormone. Nature 274: 64–66 (1978).

21. Bakhle, Y., Hartiala, J., Toivonen, H., and Uotila, P. Effect of cigarette smoke on the metabolism of vasoactive hormones by rat isolated lung. Brit. J. Pharmacol. 69: 355P–356P (1978).

22. Parke, D., and Eling, T. The influence of environmental agents on prostaglandin biosynthesis and metabolism in the lung. Bioch. J. 146: 549–556 (1976).

23. Chaudhary, A., Sivarajah, K., Warnock, R., Eling, T., and Anderson, M. Inhibition of pulmonary prostaglandin metabolism by exposure of animals to oxygen or nitrogen dioxide. Biochem. J. 184: 51–57 (1979).

24. Mathe, A., Hedgpeth, P., Strandberg, K., and Leslie, C. Aspects of prostaglandin function in the lung. New Engl. J. Med. 296: 850–855 (1977).

25. Siros, P., Bogeart, P., Jeanson, A., Roy, S., and Gerard, A. The
action of leuketiene B$_4$ (LTB$_4$) on the lung. Prostagl. Med. 5: 429–444 (1980).

26. Samuelsson, B., Goldyne, M., Granstrom, E., Hamberg, M., Hammarstrom, S., and Malmsten, C. Prostaglandins and thromboxanes. Ann. Rev. Biochem. 47: 997–1029 (1978).

27. Piper, P., and Vane, J. The release of prostaglandins from the lung and alter tissue. Ann. New York Acad. Sci. 180: 363–385 (1971).

28. Anggard, E. The isolation and determination of prostaglandins in lungs of sheep, guinea pig, monkey and man. Biochem. Pharmacol. 14: 1507–1516 (1965).

29. Dawson, W., Boot, J., Cockerill, A., Mallen, D., and Osborne, D. Release of novel prostaglandins and thromboxanes after immunological challenge of guinea pig lung. Nature 252: 699–702 (1976).

30. Hensby, C., Dollery, C., Barnes, P., and Dargie, H. Production of 6-oxo-PGF$_1$-an in human lungs in vivo. Lancet I: 1165–1168 (1979).

31. Piper, P., and Walker, J. The release of spasogenic substances from human chopped lung tissue and its inhibition. Brit. J. Pharmacol. 47: 291–304 (1975).

32. Palonek, E., Korbut, R., Gryglewski, T., and Gryglewski, R. Mass-spectrometric evidence for spontaneous and angiotensin-induced generation of prostacyclin by perfused rat lungs. Prostaglandins 20: 983–1006 (1980).

33. Voelkel, N., Gerber, J., McMurtry, I., Reaves, J., and Nies, A. Release of dilator prostaglandins from rat lung during angiotensin II-induced vasoconstriction. Adv. Prostaglandins Thromboxane Res. 7: 957–960 (1980).

34. Pace-Asciak, C., Carrana, M., Levine, L., and Nicolaou, K. PGH$_2$-specific antibodies administered in vivo, suggested against a role for endogenous PGH$_2$ as a circulating vasodepressor hormone in the normotensive and spontaneously hypertensive rat. Prostaglandins 20: 1033–1060 (1980).

35. Frolich, J., Ogletree, M., Peskar, B., and Brigham, K. Pulmonary hypertension correlate to pulmonary thromboxane synthesis. Adv. Prostaglandins Thromboxane Res. 7: 745–750 (1980).

36. Chow, C., and Tappel, A. Activities of pentose shunt and glycolytic enzymes in lungs of ozone-exposed rats. Arch. Environ. Health 26: 205–208 (1973).

37. Mustafa, M., and Tierney, D. Biochemical and metabolic changes in the lung with oxygen, ozone, and nitrogen dioxide toxicity. Am. Rev. Respir. Dis. 118: 1061–1090 (1978).

38. Crutchley, D., Boyd, J., and Eling T. Enhanced TXB$_2$ release from challenged guinea pig lung after oxygen exposure. Am. Rev. Respir. Dis. 121: 695–699 (1980).

39. Zenser, T., Levitt, M., and Davis, B. Effects of oxygen and solute on PGE and PGF production by rat kidney slices. Prostaglandins 10: 143–151 (1977).

40. Pace-Asciak, C., and Rangaraj, G. Distribution of prostaglandin biosynthetic pathways in several rat tissues. Formation of 6-keto-prostaglandin F$_1$ by calf kidney. Biochem. Biophys. Acta 486: 579–582 (1977).

41. Hamberg, M., and Samuelsson, B. Prostaglandin endoperoxide VII. Novel transformations of arachidonic acid in guinea pig lung. Biochem. Biophys. Res. Commun. 61: 942–948 (1974).

42. Alabaster, V. Metabolism of arachidonic acid and its endoperoxide (PGH$_2$) to myotrophic products in guinea pig and rabbit isolated lungs. Brit. J. Pharmacol. 69: 479–489 (1980).

43. Svensson, J., Hamberg, M., and Samuelsson, B. Prostaglandin endoperoxides. IX. Characterization of rabbit aorta contracting substance (RCS) from guinea pig lung and human platelets. Acta Physiol. Scand. 94: 222–228 (1975).

44. Nilkamp, F., Moncada, S., White, H., and Vane, J. Division of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A$_2$, bioynthesis in lung, spleen or platelets. Eur. J. Pharmacol. 44: 179–186 (1977).

45. Parkes, D., and Eling, T. Characterization of prostaglandin synthetase in guinea pig lung: isolation of a new prostaglandin derivative from arachidonic acid. Biochemistry 13: 2598–2604 (1974).

46. Moncada, S., and Vane, J. Pharmacology and endogenous role of prostaglandin endoperoxides, thromboxane A$_2$ and prostacyclin. Pharm. Rev. 36: 293–331 (1979).

47. AI Ubadaik and Bakle. Personal communication.

48. Siros, P., Engineer, D., Piper, P., and Moore, E. Comparison of rat, mouse, guinea pig, and human slow reacting substance of anaphylaxis (SRS-A). Experientia 35: 361–363 (1979).

49. Powell, W., and Solomon, S. Biosynthesis of prostaglandins and thromboxane B$_2$ by fetal lung homogenates. Prostaglandins 15: 351–363 (1978).

50. Pace-Asciak, C. Prostaglandin biosynthesis and catabolism in the developing fetal sheep lung. Prostaglandins 13: 649–660 (1977).

51. Tai, H.-Y., Yuan, B., and Wu A. Transformation of arachidonic into 6-oxoprostaglandin F$_1$ thromboxane B$_2$ and prostaglandin E$_2$ by sheep lung microsomal fraction. Bioch. J. 170: 441–444 (1978).

52. Sun, F., Chapman, J., and McGuire, J. Metabolism of prostaglan-
din endoperoxide in animal tissue. Prostaglandins 14: 1055–1074 (1977).

53. Tai, H., Tai, C., and Lee, N. Selective inhibition of thromboxane synthetase by pyridine and its derivatives. Arch. Biochem. Biophys. 302: 758–763 (1980).

54. Torusai, V., Cristina, M., and Bartolini, G. Biosynthesis of prostacyclin in rat liver endothelial cells and its control by PGE$_2$. Nature 278: 670 (1978).

55. Eling, T., Warnock, R., Dick, D., and Tainer, J. Separation of prostaglandins thromboxanes, hydroxyfatty acids and arachidonic acid by HPLC. Prostagl. Med. 5: 345–355 (1980).

56. Gryglewski, R. A new circulatory hormone: prostacyclin. Bull. Mem. Acad. Roy. Med. Belg. 133: 470–474 (1978).

57. Korbut, R., Boyd, J., and Eling, T. Respiratory movements alter the generation of prostacyclin and thromboxane A$_2$ in isolated rat lung: the influence of arachidonic acid pathway inhibitors on the ratio between pulmonary PGD$_2$ and TXA$_2$. Prostaglandins 21: 491–509 (1981).

58. Hong, S., Carty, T., and Deykin, D. Tranlecyromine and 15 hydroperoxysterachidonate effect arachidonate release in addition to inhibition of prostacyclin synthesis in calf aortic cells. J. Biol. Chem. 255: 9539–9540 (1980).

59. Ally, A., and Horrobin, D. Vascular smooth muscle synthesis of thromboxane A$_2$ and inhibition by pharmacological agents. Can. Fed. Biol. Soc. 22: 466 (1979).

60. Salzman, P., Salmon, J., and Moncada, S. Prostacyclin and thromboxone A$_2$ synthesis by rabbit pulmonary artery. J. Pharmacol. Expvl. Therap. 215: 240–247 (1980).

61. Levine, L., and Alam, I. Arachidonic acid metabolism by cells in culture: analyses of culture fluids for cyclooxygenase products by RIA before and after separation by high performance liquid chromatography. Prostagl Med. 3: 295–304 (1979).

62. Boyd, J. A., and Eling, T. E. Prostaglandin release and interaction of platelets with the pulmonary vasculature of rat and guinea pig. Thrombosis Res. 11: 239–248 (1980).